AbbVie Inc. Buyback
OLI recorded this information on 12/13/2018
The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program.
AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
AbbVie SEC Filing Email Alerts Service
Open the ABBV Page at The Online Investor »
Free ABBV Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (3.03 out of 4)